1. |
Havens SJ, Gulati V. Neovascular glaucoma[J]. Dev Ophthalmol, 2016, 55: 196-204. DOI: 10.1159/000431196.
|
2. |
Hayreh SS. Neovascular glaucoma[J]. Prog Retin Eye Res, 2007, 26(5): 470-485. DOI: 10.1016/j.preteyeres.2007.06.001.
|
3. |
Sun Y, Liang Y, Zhou P, et al. Anti-VEGF treatment is the key strategy for neovascular glaucoma management in the short term[J/OL]. BMC Ophthalmol, 2016, 16(1): 150[2016-08-30]. https://pubmed.ncbi.nlm.nih.gov/27576739/. DOI: 10.1186/s12886-016-0327-9.
|
4. |
Sun JT, Liang HJ, An M, et al. Efficacy and safety of intravitreal ranibizumab with panretinal photocoagulation followed by trabeculectomy compared with Ahmed glaucoma valve implantation in neovascular glaucoma[J]. Int J Ophthalmol, 2017, 10(3): 400-405. DOI: 10.18240/IJO.2017.03.12.
|
5. |
Mahdy RA, Nada WM, Fawzy KM, et al. Efficacy of intravitreal bevacizumab with panretinal photocoagulation followed by ahmed valve implantation in neovascular glaucoma[J]. J Glaucoma, 2013, 22(9): 768-772. DOI: 10.1097/IJG.0b013e318259aec4.
|
6. |
Tang M, Fu Y, Wang Y, et al. Efficacy of intravitreal ranibizumab combined with ahmed glaucoma valve implantation for the treatment of neovascular glaucoma[J/OL]. BMC Ophthalmol, 2016, 16: 7[2016-01-09]. https://pubmed.ncbi.nlm.nih.gov/26749079/. DOI: 10.1186/s12886-016-0183-7.
|
7. |
Iliev ME, Domig D, Wolf-Schnurrbursch U, et al. Intravitreal bevacizumab (Avastin) in the treatment of neovascular glaucoma[J]. Am J Ophthalmol, 2006, 142(6): 1054-1056. DOI: 10.1016/j.ajo.2006.06.066.
|
8. |
Shen X, Chen Y, Wang Y, et al. Intravitreal ranibizumab injection as an adjuvant in the treatment of neovascular glaucoma accompanied by vitreous hemorrhage after diabetic vitrectomy[J/OL]. J Ophthalmol, 2016, 2016: 4108490[2016-05-16]. https://pubmed.ncbi.nlm.nih.gov/27293875/. DOI: 10.1155/2016/4108490.
|
9. |
Liu L, Xu Y, Huang Z, et al. Intravitreal ranibizumab injection combined trabeculectomy versus ahmed valve surgery in the treatment of neovascular glaucoma: assessment of efficacy and complications[J/OL]. BMC Ophthalmol, 2016, 16: 65[2016-05-26]. https://pubmed.ncbi.nlm.nih.gov/27230388/. DOI: 10.1186/s12886-016-0248-7.
|
10. |
Simha A, Aziz K, Braganza A, et al. Anti-vascular endothelial growth factor for neovascular glaucoma[J/OL]. Cochrane Database Syst Rev, 2020, 2(2): CD007920[2020-02-06]. https://pubmed.ncbi.nlm.nih.gov/32027392/. DOI: 10.1002/14651858.CD007920.pub3.
|
11. |
Olmos LC, Sayed MS, Moraczewski AL, et al. Long-term outcomes of neovascular glaucoma treated with and without intravitreal bevacizumab[J]. Eye (Lond), 2016, 30(3): 463-472. DOI: 10.1038/eye.2015.259.
|
12. |
Sun C, Zhang HS, Yan YJ, et al. Early vitrectomy combined with pan retinal photocoagulation, anti-vascular endothelial growth factor, and gradual cyclophotocoagulation for treatment of neovascular glaucoma[J]. Chin Med J (Engl), 2019, 132(20): 2518-2520. DOI: 10.1097/CM9.0000000000000482.
|
13. |
Yan H. Outcomes of 23-Gauge vitrectomy combined with phacoemulsification, panretinal photocoagulation, and trabeculectomy without use of anti-VEGF agents for neovascular glaucoma with vitreous hemorrhage[J/OL]. J Ophthalmol, 2016, 2016: 3097379[2016-01-07]. https://pubmed.ncbi.nlm.nih.gov/26885379/. DOI: 10.1155/2016/3097379.
|
14. |
Shchomak Z, Cordeiro Sousa D, et al. Surgical treatment of neovascular glaucoma: a systematic review and meta-analysis[J]. Graefe's Arch Clin Exp Ophthalmol, 2019, 257(6): 1079-1089. DOI: 10.1007/s00417-019-04256-8.
|
15. |
Higashide T, Ohkubo S, Sugiyama K. Long-term outcomes and prognostic factors of trabeculectomy following intraocular bevacizumab injection for neovascular glaucoma[J/OL]. PLoS One, 2015, 10: e0135766[2015-08-14]. https://pubmed.ncbi.nlm.nih.gov/26275060/. DOI: 10.1371/journal.pone.0135766.
|
16. |
Kim M, Lee C, Payne R, et al. Angiogenesis in glaucoma filtration surgery and neovascular glaucoma: a review[J]. Surv Ophthalmol, 2015, 60(6): 524-535. DOI: 10.1016/j.survophthal.2015.04.003.
|
17. |
Sun C, Zhang H, Tang Y, et al. Aqueous inflammation and ischemia-related biomarkers in neovascular glaucoma with stable iris neovascularization[J]. Curr Eye Res, 2020, 45(12): 1504-1513. DOI: 10.1080/02713683.2020.1762226.
|
18. |
Hong Y, Hu Y, Dou H, et al. Comparison of the safety and efficacy of triple sequential therapy and transscleral cyclophotocoagulation for neovascular glaucoma in the angle-closure stage[J/OL]. Sci Rep, 2018, 8(1): 7074[2018-05-04]. https://pubmed.ncbi.nlm.nih.gov/29728640/. DOI: 10.1038/s41598-018-25394-9.
|
19. |
Chalam KV, Brar VS, Murthy RK. Human ciliary epithelium as a source of synthesis and secretion of vascular endothelial growth factor in neovascular glaucoma[J]. JAMA ophthalmol, 2014, 132(11): 1350-1354. DOI: 10.1001/jamaophthalmol.2014.2356.
|